To the Editor We read the recent review by Yeh and Chang1 with interest and congratulate them for reinforcing the role of cardio-oncology (oncocardiology), an emergent discipline in the cardiology field. This article is timely in the context of the proliferation of new cancer therapies and the increase in the number of cancer survivors. Cardiovascular care for cancer patients has become challenging because they live longer and are at greater risk of cardiovascular events. Yeh and Chang1 pointed out the well-known toxic effects of anthracyclines, but they also underlined the cardiovascular toxicity resulting from the anti-HER2 and anti-VEGF antibodies, inhibitors of tyrosine kinases and of other intracellular signals. This description is very important because it aims at educating the cardiology community about the growing issue of cardiotoxicity in cancer patients.1
Cautela J, Lalevee N, Thuny F. Potential of Oncocardiology. JAMA Cardiol. 2017;2(7):817–818. doi:10.1001/jamacardio.2017.0119
Customize your JAMA Network experience by selecting one or more topics from the list below.